Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

Anti-CD47 gel prevents cancer recurrence after surgery

December 11, 2018 11:52 PM UTC

ZenCapsule Inc. (Los Angeles, Calif.) is developing a localized sprayable gel similar to an anti-CD47 immunotherapeutic gel described in a new paper from University of California Los Angeles researchers that prevented postsurgical cancer recurrence in mice.

Studies have suggested surgery-related inflammation incites growth and spread of dormant cancer cells, and anti-inflammatories or immunotherapies could prevent disease recurrence (see "Anti-inflammatories May Prevent Breast Cancer Recurrence")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Target Profiles

CD47